A patient-friendly
approach to
Improved Cancer
Care

Our focus is the development of
patient-friendly and preventative
therapies that make a major, positive
difference to cancer patients’ well-being
and quality of life, with substantial payer
savings potential.

Who we are

VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.

Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.

Our Programmes

Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.

Who we are

VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.

Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.

Our Programmes

Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.

The VasoDynamics Pipeline

The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.

NG11

Prevention of radiation-induced
oral mucositis (RIOM)

NG12

Prevention of radiation-induced
dermatitis

NG13

Prevention of chemotherapy-induced
alopecia (hair loss)

The VasoDynamics Pipeline

The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.

NG11

Prevention of radiation-induced
oral mucositis (RIOM)

NG12

Prevention of radiation-induced
dermatitis

NG13

Prevention of chemotherapy-induced
alopecia (hair loss)

Our Latest News:

VasoDynamics Sets-up Laboratory at Stevenage Bioscience Catalyst

Laboratory facilities initiated to optimise development of product pipeline for the prevention of cancer therapy induced side-effects

Our Latest News:

NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer